Cost-effectiveness analysis of methods of diagnosis of tb infection in russian regions by use of recombinant tb allergen in children and adolescents
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2017, Vol 2, Issue 2
Abstract
Background. Russia is among the countries with a high burden of TB. A new diagnostic method for TB has been developed, called ‘recombinant tuberculosis allergen’ or RTA (Diaskintest®), which has a similar cost and method of administration to the Mantoux test, but the principle of action, sensitivity and specificity are similar to IGRA technology. Despite the improvements of RTA, TB experts continue to use the Mantoux test. The aim of this study was to determine the most cost-effective medical technology for diagnosing tuberculosis infection in the Russian Federation, basing on calculation of ICER. Methods. The study was based on 3 models simulating the diagnosis of TB in Russia: 1-Mantoux test and further diagnostics methods (based on screening in 2008 in 1,302,490 Moscow children and adolescents); 2-Mantoux test with subsequent use of RTA in case of a positive Mantoux test, combined with further diagnostics methods (based on screening in 2013 in 1,420,100 Moscow children and adolescents); 3-RTA alone and further diagnostics methods (data based on screening conducted in 2015 in 108,729 Penza region children and adolescents 8-17 y.o.). Results. Method effectiveness (percentage of active TB infection among screened individuals), was 0.006%, 0.012% and 0.019% for models 1, 2 and 3, respectively. Cost-effectiveness ratios were 41861.67, 18401.67 and 10512.12 for models 1, 2 and 3, respectively. Conclusions. RTA is the most cost-effective tuberculosis screening method in children and adolescents, superior to both the stand-alone Mantoux test or the Mantoux test followed by RTA
Authors and Affiliations
Malwina Hołownia, Ilya Solodun, Ekaterina Bashlakova, Tatiana Ermolaeva, Maria Davydovskaya, Evgeniy Evdoshenko
Keywords
Related Articles
- EP ID EP326199
- DOI 10.7365/JHPOR.2017.2.5
- Views 80
- Downloads 0
Mepolizumab: a new drug programme for patients with severe eosinophilic asthma
Biological treatment involves more and more fields of medicine. This also applies to severe asthma for which a therapy with omalizumab (anti-IgE antibodies for patients with allergic asthma) has been available since 2013...
Assessment of thrombocytopenia symptoms using vignettes. Preliminary report on the development and implementation of a new instrument
Objective: Our aim was to create a vignette enabling the assessment of the impact of thrombocytopenia symptoms on patients’ quality of life. Methods: The vignettes which we created are focused on thrombocytopenia sym...
Real-life treatment patterns and medication costs in patients with hypertension treated with ramipril monotherapy or ramipril loose and fixed combinations in Poland
Background: Real-World Evidence (RWE) provides insights into patient outcomes reflecting current practices under existing healthcare system conditions. Longitudinal patient data are a source of information that can be us...
Comparator outcomes profile: need for an informed assessment of secondary outcomes for conducting post-launch observational studies in the HE&OR setting
Secondary clinical and health outcomes provide additional value and help drug molecule distinguish itself from competitor molecules. Comparator outcomes profile (COP) document in health economics and outcomes research (H...
Primary immunodeficiencies – epidemiology, spending on therapy, diagnostic and therapeutic needs in Poland
Abstract Primary immunodeficiencies (PID) are a heterogeneous group of over 300 diseases of the immune system characterised by its disfunction, and in consequence by chronic or recurrent infections, autoimmunity, aller...